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1. Introduction 
Multiple sclerosis (MS) is a chronic disease of the central nerve system (CNS) primarily 
affecting youngsters. The CNS has a potent antioxidant defense mechanism to scavenge 
reactive oxygen species (ROS). MS can be effectively studied in animal models with 
experimental autoimmune encephalomyelitis (EAE). The immunopathogenic mechanisms 
involved in EAE are attributed to T-cell-mediated inflammatory disease of the CNS and 
activation of T cells, which recruit invading inflammatory cells, such as macrophages. The 
activated T cells also induce astrocytes and microglia in situ to secrete cytokines, 
chemokines, and toxic molecules, namely, glutamate, nitric oxide (NO), and/or ROS, which 
in turn contribute to axonal damage. These processes are followed by complement 
activation and antibody-mediated phagocytosis of axons, which eventually lead to 
demyelination and axonal injury. 
Brain tissue of MS patients was found to express antioxidants, and MS lesions have been 
reported to express high levels of antioxidants, indicating oxidative stress (OS). Heme 
oxygenase-1 (HO-1) is a heat-shock protein induced by OS; this protein was found to be 
expressed in active MS lesions and in EAE. Therefore, it can be inferred that ROS may play a 
distinct role in the pathogenesis of MS and that antioxidants may inhibit the development 
and progression of MS lesions. In this chapter, we summarize immunomodulation and 
therapeutic strategies in MS and examine experimental and clinical evidence to assess the 
applicability of the novel strategy of using antioxidants, such as melatonin, statins, ǂ-lipoic 
acid (ALA), natural compounds (flavonoids), and erythropoietin (EPO), as adjuvant 
treatment in MS.  
2. Roles of OS in MS  
The initial stages of the formation of MS lesions are primarily characterized by the activation 
of residential microglia by autoreactive Th cells, while the active phase of the MS lesion is 
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characterized by the infiltration of the lesion area by monocyte-derived macrophages, which 
initiate demyelination [Schreiner et al., 2009; van der Valk and De Groot, 2000]. Both 
activated microglia and infiltrated macrophages can generate excessive amounts of 
proinflammatory mediators and oxidizing radicals, such as superoxide, hydroxyl radicals, 
hydrogen peroxide, and NO [Colton and Gilbert, 1993; Gilgun-Sherki et al., 2004]. MS is 
most commonly studied in animal models of EAE. The immunopathogenesis of EAE is 
widely believed to involve T-cell-mediated inflammatory disease of the CNS, wherein 
activated T cells recruit macrophages and resident astrocytes and microglia, leading to the 
release of inflammatory mediators and cytotoxic molecules, namely, glutamate, NO, and/or 
ROS, which contribute to axonal damage; this is then followed by complement activation or 
antibody-mediated phagocytosis of axons [Hisahara et al., 2003; Schreibelt et al., 2007]. 
Furthermore, axonal degeneration in MS lesions can be divided into 2 steps: an initial stage 
of acute axonal injury in the inflammatory MS lesion [Ferguson et al., 1997; Trapp et al., 
1998] and subsequent “slow burning” or axonal degeneration in non-inflammatory chronic 
lesions [Kornek et al., 2000]. The pathological changes in MS are also characterized by the 
presence of demyelinating plaques within the gray matter [Frohman et al., 2006]. 
Nevertheless, mitochondrial dysregulation and mitochondria-derived ROS have been 
reported to contribute to axonal damage in MS [Kalman et al., 2007; Mahad et al., 2009; Su et 
al., 2009; van Horssen et al., 2010; Witte et al., 2009]. In addition, a subset of activated 
microglia was found in cortical lesions, suggesting that microglia-derived ROS might 
contribute to gray matter demyelination [Gray et al., 2008]. Taken together, these evidences 
indicate that ROS play a pivotal role in several processes underlying the formation and 
persistence of MS lesions.  
Experimental animal studies have demonstrated that the dietary intake of exogenous 
antioxidants, including flavonoids and ǂ-lipoic acid, reduces the progression and clinical 
signs of EAE [Chaudhary et al., 2006; Hendriks et al., 2004; Marracci et al., 2002; 
Theoharides, 2009; Verbeek et al., 2005]. Despite promising results observed in animal 
models of MS, data on successful antioxidant therapy in MS patients is still limited; this 
emphasizes the need for epidemiological and clinical studies on this treatment strategy in 
MS. Reports indicate that antioxidants need be administered in high quantities to exert their 
protective effects in animal models of MS [Gilgun-Sherki et al., 2004; Mirshafiey and 
Mohsenzadegan, 2009]. Since ROS play a pivotal role in the initial phase as well as the 
chronic stage of MS, antioxidant therapy may be suitable for limiting overall disease 
progression. Thus, further understanding of the immunomodulatory activities of potential 
protective antioxidants is vital for their application in MS [Schreibelt et al., 2007; van 
Horssen et al.].  
2.1 HO-1 in EAE/MS 
HO-1 is a heat-shock protein induced by OS. In HO-1-expressing cells, the association of 
reductase with HO-1 competitively limits the interaction of reductase with cytochrome P450 
isozymes, and thereby, the resultant production of superoxide; this reduced interaction 
limits free radical production and prevents oxidative damage of DNA, thereby suppressing 
oxidative or proinflammatory tissue damage [Prawan et al., 2005]. HO-1 has both 
antioxidative and anti-inflammatory activities and is highly inducible by a variety of stimuli, 
including its substrates heme and OS [Schipper, 2004]. Lee and Chau demonstrated that the 
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overexpression of HO-1 in macrophages can inhibit proinflammatory response via 
lipopolysaccharide (LPS) stimulation and that IL-10 and HO-1 activate a positive feedback 
circuit to enhance the anti-inflammatory response both in vitro or in vivo [Lee and Chau, 
2002]. In addition, Ponomarev et al. found that increased expression of IL-4 in glial cells was 
associated with reduced severity of EAE and that IL-4 production in the CNS is crucial for 
controlling autoimmune inflammation by inducing an alternative pathway for the 
regulation of microglial cells, but IL-4 production in the peripheral circulation was not 
found to have this effect [Ponomarev et al., 2007]. In contrast, Lee and Suk showed that IL-
10 and IL-4 levels did not have any effect on the overexpression of HO-1 in LPS-stimulated 
microglia in vitro [Lee and Suk, 2007]. However, Zenclussen et al. found that the 
upregulation of HO-1 by using an adenoviral vector system expressing the HO-1 gene 
(AdHO-1) has a protective effect against fetal rejection in the murine abortion model; they 
also found that compared to abortion-prone mice, AdHO-1-treated mice showed higher 
values of the systemic and local IL-4/IFN-Ǆ ratios and the IL-10/TNF-ǂ ratio in the spleen 
[Zenclussen et al., 2006].  
HO-1 has been detected in EAE lesions, and significant amplification of HO-1 protein levels 
has been proved in animal models of EAE [Schluesener and Seid, 2000]. HO-1 expression 
has also been reported in active MS lesions [van Horssen et al., 2008]. This enhanced 
expression of endogenous HO-1 may be one of the mechanisms involved in minimizing 
tissue damage in EAE [Emerson and LeVine, 2000]. Evidence has also shown that Hmox1(-
/- )C57BL/6 mice, i.e., HO-1 gene knockout mice, displayed greater severity of EAE as 
compared to Hmox1(+/+) mice. Further, induction of HO-1 by cobalt protoporphyrin IX 
(CoPPIX) administration has been shown to suppress EAE progression, but this protective 
effect of CoPPIX was abrogated in Hmox1(-/-) mice with EAE [Chora et al., 2007]. Thus, 
endogenous HO-1 expression may play an important protective role in EAE, and therefore, 
the induction of HO-1 overexpression may represent a novel therapeutic strategy for MS 
[Liu et al., 2001].  
2.2 Inflammation and immunopathogenesis of ROS and NO in MS  
Brain tissue is very vulnerable to free radical damage because of its high oxygen utilization 
(20% of the total oxygen inspired); high concentrations of polyunsaturated fatty acids [Floyd 
and Hensley, 2002] and transition metals, such as iron, which are involved in the generation 
of the hydroxyl radical [Hill and Switzer, 1984]; and low concentrations of cytosolic 
antioxidants [Floyd and Carney, 1993; Reiter, 1995b]. In the brain, NO plays crucial roles in 
neuromodulation, neurotransmission, maintenance of synaptic plasticity, etc., and it also 
mediates pathological processes such as neurodegeneration and neuroinflammation [Golde 
et al., 2002]. Thus, NO may inhibit neuronal respiration, and NO production by astrocytes is 
believed to contribute to the neurodegenerative process via the impairment of 
mitochondrial function.  
In addition, neuronal injury has also been reported to be associated with NO released by 
glial cells [Bal-Price and Brown, 2001; Mander et al., 2005]. Although glial activation can be 
protective, excess activation can be detrimental [Murphy, 1999]. Glia are activated by 
inflammatory mediators and express new proteins such as inducible NO synthatase (iNOS) 
[Emerit et al., 2004]. NO produced by the action of iNOS appears to be a key mediator of 
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glia-induced neuronal death. Astroglial cells are “activated” in a wide range of CNS 
disorders, leading to the induction of iNOS [Bolanos et al., 1997; Endoh et al., 1994]. In 
mouse models of EAE, immunohistochemistry revealed elevated activity levels of iNOS in 
inflammatory lesions of the CNS, suggesting that excessive NO production due to activity of 
iNOS may play an essential role in eradicating inflammatory cells in the CNS of mice with 
EAE [Okuda et al., 1997]. 
A chronic inflammatory state gives rise to an activated immune response, which involves an 
acute phase protein response and the release of proinflammatory cytokines, macrophages, 
lymphocytes, and other immune system cells [Murakami, 2009; Taupin, 2008]. This 
complicated process triggers the recruitment of innate immune cells, which in turn mediates 
demyelination and axonal damage, and the formation of lesions that generally consist of T 
cells, macrophages, and microglia. OS plays a critical role in the pathogenesis of MS. ROS, 
which are generated in excess amounts mainly by macrophages subjected to OS, have been 
implicated in the demyelination and axonal damage occurring in both MS and EAE [Gilgun-
Sherki et al., 2004]. NO has also been identified in the spinal cords of mouse models of EAE, 
indicating the potential role of NO in the pathogenesis of EAE, and possibly MS [Lin et al., 
1993].  
Increased levels of the indicators of OS and/or decreased levels of antioxidant enzymes and 
antioxidants have been detected in the blood and cerebrospinal fluid of MS patients in the 
active phases of the disease; these findings indicate that increased levels of ROS may cause 
the depletion of cellular antioxidants [van der Goes et al., 1998; van Horssen et al., 2010; van 
Meeteren et al., 2005]. In recent decades, immunologic cascade and inflammation have been 
proposed as causative factors of neurological diseases and autoimmune disorders, such as 
MS [Taupin, 2008]. On the basis of currently available findings, we assessed the usefulness 
of statins, melatonin, ALA, natural antioxidant compounds, and EPO, as potential 
candidates for adjuvant therapy in MS patients, by virtue of for their antioxidant and 
immunomodulatory proprieties. 
3. Statins in MS/EAE 
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (or statins) 
are powerful cholesterol-lowering drugs, which are beneficial to the primary and secondary 
prevention of coronary heart disease; these drugs can improve endothelial function, increase 
NO bioavailability, exhibit antioxidant activity, stabilize atherosclerotic plaques, regulate 
progenitor cells, inhibit inflammatory responses, and exert immunomodulatory effects 
[Endres, 2006]. Pahan et al. reported that lovastatin inhibits the induction of iNOS and 
expression of proinflammatory cytokines in rat primary glial cells (astroglia and microglia) 
and macrophages [Pahan et al., 1997]. Subsequently, Stanislaus et al. showed that 
proinflammatory cytokines and iNOS are involved in the pathogenesis of EAE [Stanislaus et 
al., 1999] and thus highlighted the therapeutic importance of lovastatin in inhibiting the 
neuroinflammatory processes in the CNS and the central expression of iNOS, TNF-ǂ, and 
IFN-Ǆ in EAE; this suggests that lovastatin may have therapeutic potential in the treatment 
of neuroinflammatory diseases, such as MS [Stanislaus et al., 1999].  
Atorvastatin exhibits pleiotropic immunomodulatory activity against both antigen-
presenting cells (APC) and T-cell compartments. For instance, Youssef et al. reported that 
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atorvastatin treatment of microglia inhibits IFN-Ǆ-inducible transcription of multiple major 
histocompatibility complex (MHC) class II transactivator (CIITA) promoters and suppresses 
the upregulation of class II MHC [Youssef et al., 2002]. In addition, they found that 
atorvastatin suppresses IFN-Ǆ-inducible expression of CD40, CD80, and CD86 co-
stimulatory molecules, as well as L-mevalonate, thereby indicating that statins may be 
beneficial in the treatment of MS and other Th1-mediated autoimmune diseases [Youssef et 
al., 2002]. 
Nath et al. demonstrated that lovastatin inhibits EAE by modulating T-cell as well as APC 
responses and that the effects of lovastatin on macrophage/microglia in an Ag-non-specific 
system suggest that lovastatin is not only effective in EAE. Their study also revealed that 
lovastatin inhibits the transcription factors T-bet, NF-κB, and STAT4, which are responsible 
for CNS inflammation, via the induction of Th1 cell differentiation and production of related 
cytokines, such as IFN-Ǆ and TNF-ǂ. In addition, lovastatin induces the expression of 
GATA3 and STAT6 in Th2 cells and contributes to the downregulation of IFN-Ǆ/T-bet in 
Th1 cells [Nath et al., 2004]. Statins have been reported to have potential for use as novel 
therapeutic agents to reverse the established paralysis in MS and to exert beneficial effects in 
synergy with other agents already approved for MS therapy [Weber and Zamvil, 2008]. 
However, simvastatin administered along with interferon ǃ-1a as add-on therapy for at least 
1–3 years in patients with relapsing–remitting MS (SIMCOMBIN study) did not show any 
beneficial effects in a placebo-controlled randomized phase 4 clinical trial [Sorensen et al.]. 
Similarly, a cohort study revealed that the disability progression in MS did not differ 
significantly between MS patients receiving and those not receiving statin therapy, thereby 
suggesting that statins do not affect the long-term course of MS [Paz Soldan et al.]. 
However, the combination of other statins with other disease-modifying drugs may be 
beneficial in MS. More clinical data is required to clarify this issue. 
4. Melatonin in MS/EAE 
Melatonin (5-methoxy-N-acetylserotonin) is mainly produced in the pineal gland during the 
dark phase of the day-night cycle, and it displays multifunctional properties and 
characteristics of a potent antioxidant [Martin et al., 2000]. In addition, melatonin is involved 
in the regulation of aging [Pierpaoli and Regelson, 1994] and scavenging of free hydroxyl 
radicals [Reiter, 1995a]. Melatonin is now well-known as a powerful antioxidant; an 
increasing number of experimental evidences have shown its protective effects against OS-
induced macromolecular damage and diseases, including those involving mitochondrial 
dysfunction [Acuna et al., 2002]. Furthermore, melatonin exhibits both direct and indirect 
antioxidant activity, scavenges free radicals, stimulates antioxidant enzymes, enhances the 
activities of other antioxidants, and protects other antioxidant enzymes from oxidative 
damage [Castroviejo et al., 2011; Esposito and Cuzzocrea, 2010].  
The results of numerous clinical studies have indicated that melatonin is a neuroprotective 
molecule in neurodegenerative disorders, which are believed to involve widespread brain 
oxidative damage [Esposito and Cuzzocrea, 2010; Kaur and Ling, 2008]. For example, 
melatonin defeats neurally derived free radicals and reduces the associated 
neuromorphological and neurobehavioral damage [Reiter et al., 2007]. Melatonin inhibits 
the expression of the iNOS in murine macrophages by inhibiting NF-κB activation [Gilad et 
al., 1998] and suppressing the levels of intercellular adhesion molecule (ICAM)-1 in 
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experimental spinal cord reperfusion injury [Cuzzocrea et al., 2000]. Constantinescu et al 
reported that melatonin is capable of immunomodulation via the activation of NK cells 
[Constantinescu et al., 1997], upregulation of Th2 response, and inhibition of NF-κB 
[Maestroni, 1995]. Thus, both experimental and clinical data show that melatonin reduces 
the expression of adhesion molecules and pro-inflammatory cytokines and modifies serum 
inflammatory parameters. 
Since the abovementioned findings indicate that melatonin exhibits both anti-inflammatory 
and immunomodulatory activities, it can be considered effective in suppressing 
autoimmune diseases, including EAE [Constantinescu, 1995; Sandyk, 1997]. Moreover, Kang 
et al. demonstrated that melatonin ameliorates EAE through the suppression of ICAM-1 
levels. They also reported that melatonin treatment increases T-cell proliferation in mice and 
enhances the production of NK cells and monocytes in the bone marrow of mice, suggesting 
that it plays an important role in the immune system; thus, exogenous melatonin has been 
shown to ameliorate EAE by reducing the expression of ICAM-1 and lymphocyte function-
associated antigen-1a (LFA-1ǂ) in autoimmune target organs [Kang et al., 2001]. On the 
other hand, Maestroni et al. showed that melatonin treatment of mice decreases the 
expression of IL-2 and IFN-Ǆ and upregulates the expression of Th2 cell cytokines, such as 
IL-4 and IL-10 [Maestroni, 1995]. Lin et al. found that melatonin prolongs islet graft survival 
in nonobese diabetic (NOD) mice via the reduction of Th1 cell and T-cell proliferation and 
elevating IL-10 levels, thereby indicating that melatonin treatment suppresses autoimmune 
recurrence after graft implantation [Lin et al., 2009]. Thus, melatonin plays a role in 
immunomodulation by regulating cytokine production of immunocompetent cells. From 
these findings, melatonin may be considered effective in improving the clinical course of 
autoimmune inflammatory diseases. 
A clinical study by Akpinar et al. revealed that nocturnal serum melatonin levels were 
associated with major depression in acute MS patients, suggesting that melatonin deficiency 
may contribute to the occurrence of depression in MS patients [Akpinar et al., 2008b]. 
Moreover, Anderson et al. demonstrated that the optimization of melatonin and vitamin D3 
inhibits the effects of IL-18 on the symptoms and cell loss of MS, as well as microglia and T-
cell activation [Anderson and Rodriguez, 2011]. In addition, they confirmed that valproate 
treatment may interact significantly with melatonin and vitamin D3 to inhibit seizures and 
other signs and symptoms of MS [Anderson and Rodriguez, 2011]. Thus, the understanding 
of the immunomodulatory and anti-oxidative activity of melatonin in EAE may enable the 
therapeutic application of this molecule in MS.  
5. ALA in MS/EAE 
ALA (or 1,2-dithiolane-3-pentanoic acid) is a naturally occurring dithiol compound 
synthesized enzymatically in the mitochondrion from octanoic acid (Curr. Med. Chem. 11 
(2004) 1135-1146.); it is an essential cofactor of key mitochondrial enzymes that control 
glucose oxidation, such as pyruvate dehydrogenase and ǂ-ketoglutarate dehydrogenase 
[Gohil et al., 1999]. ALA mainly acts as a natural antioxidant that scavenges ROS and 
regenerates or recycles endogenous antioxidants (Free Radic. Res. 20 (1994) 119-133.). ALA 
and its reduced dithiol form, dihydrolipoic acid (DHLA), are potent antioxidants in both fat- 
and water-soluble media. In addition, ALA reacts with superoxide and hydroxyl radicals, 
hypochlorous acid, peroxyl radicals, and singlet oxygen [Marangon et al., 1999]. ALA also 
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recycles vitamins C and E and increases the intracellular glutathione concentration. The 
antioxidative effect of ALA may be partially mediated by the chelation of transition metals, 
modification of the redox status of thiol-containing proteins, and inhibition of redox-
sensitive nuclear transcription factors [Abdul and Butterfield, 2007; Akpinar et al., 2008a; 
Moini et al., 2002]. Tirosh et al. have previously shown that LA-plus is a potent protector of 
neuronal cells against glutamate-induced cytotoxicity and associated oxidative damage 
[Tirosh et al., 1999]. Further, Cheng et al. reported that ALA protects the cardiovascular 
system against oxidative injury` [Cheng et al., 2006]. They also found that ALA significantly 
increased the expression levels of HO-1 and ROS production and increased HO activity in 
A10 cells and the resistance of A10 cells to hydrogen-peroxide-induced OS; this effect was 
blocked by N-acetyl-cysteine, which also inhibited ALA-induced activation of p44/42 
mitogen-activated protein kinase (MAPK) and AP-1, HO-1 expression, and HO activity. 
These findings suggest that ALA induces HO-1 expression through the production of ROS 
and subsequent activation of the p44/42 MAPK pathway and AP-1 in vascular smooth 
muscle cells and that it increases the expression of HO-1, which is a critical cytoprotective 
molecule [Cheng et al., 2006]. 
van der Goes et al. reported that ROS appear to be involved in the regulation of the 
phagocytosis of myelin and that lipoic acid (LA), a non-specific scavenger of ROS, also 
decreased the phagocytosis of myelin by macrophages [van der Goes et al., 1998].  
Marracci et al. have shown that ALA ameliorates EAE in SJL mice immunized with 
proteolipid protein (PLP) 139-151 peptide, resulting in minimal inflammation characterized 
by less demyelination and only mild axonal loss in the spinal cords; they also demonstrated 
a marked reduction in the expression of CD3+ T cells and CD11b+ monocyte/macrophage 
cells in the affected spinal cord. Further, ALA and its reduced form, DHLA, inhibited the 
activity of matrix metalloproteinase-9 (MMP-9) in a dose-dependent manner [Marracci et al., 
2002]. This was associated with a reduction in the number of CNS-infiltrating T cells and 
macrophages as well as decreased demyelination. Morini et al. further tested ALA in a 
therapeutic protocol aimed at suppressing myelin oligodendrocyte glycoprotein (MOG)-
EAE; they also found significant reduction of demyelination and inflammatory infiltration 
and in the number of MOG-specific T cells, resulting in decreased production of IFN-Ǆ and 
IL-4; this suggests that ALA exerts immunosuppressive activity on both Th1 and Th2 
cytokines [Morini et al., 2004].  
Marracci et al. showed that both ALA and DHLA inhibited Jurkat cell migration and have 
different mechanisms for inhibiting MMP-9 activity. These data together with the finding 
that ALA can ameliorate relapsing EAE suggest that ALA merits investigation as a 
therapeutic agent for MS [Marracci et al., 2004]. Moreover, Schreibelt et al. reported that 
antioxidant LA dose-dependently prevented the clinical development of EAE in a rat model 
of MS, along with a decrease in the CNS infiltration of leukocytes, particularly monocytes, 
which may be reflected as reduced ability to cross the blood brain barrier (BBB) [Schreibelt 
et al., 2006].  
Accordingly, oxidative injury is recognized as an important process in the pathogenesis of 
MS. The powerful antioxidant property of ALA may render it a good candidate for adjuvant 
treatment in EAE/MS. In addition, ALA is greatly effective in suppressing and treating 
EAE; this effect is mediated by the inhibition of T-cell trafficking into the spinal cord, 
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possibly by inhibiting MMP. Thus, ALA impedes the development of EAE not only by 
serving as an antioxidant but also by affecting the migratory capacity of monocytes and by 
stabilizing the BBB; these features make ALA an attractive therapeutic agent for MS 
6. Potential of natural food compounds in the treatment of EAE/MS 
Aktas et al. reported that the green tea extract epigallocatechin-3-gallate (EGCG) reduced 
the clinical severity of EAE when administered at the initiation or after the onset of the 
condition; this effect of EGCG is believed to be mediated by the limiting of brain 
inflammation and reducing neuronal damage, which are mediated by NF-kappa B 
inhibition, abrogated proliferation and TNF-alpha production of encephalitogenic T cells, 
and direct blocking of the formation of neurotoxic ROS in neurons [Aktas et al., 2004]. Thus, 
natural green tea components that have antioxidant, anti-inflammatory, and 
neuroprotective activities, may be considered novel candidates for the treatment of MS. 
6.1 Natural compounds repress MMP to protect EAE/MS 
Hendriks et al. have shown that flavonoids, which are naturally occurring compounds of 
green tea, can influence myelin phagocytosis by macrophages in vitro. The flavonoids 
luteolin, quercetin (3,3′4′,5,7-pentahydroxy flavone), and fisetin most significantly reduce 
the extent of invasion of myelin phagocytes, without affecting their viability; this implies 
that they may be capable of restricting the demyelination process involved in MS [Hendriks 
et al., 2003]. On similar lines, Theoharides found that luteolin and structurally similar 
flavonoids can inhibit EAE and suggested that an appropriate luteolin formulation that 
permits sufficient absorption and reduces its metabolism could be a useful adjuvant to IFN-
ǃ in the treatment of MS [Theoharides, 2009]. A study by Muthian et al. on SJL/J mouse 
models of EAE revealed that quercetin (QRC), a flavonoid phytoestrogen, ameliorates EAE 
in vivo by inhibiting IL-12 production and neural antigen-specific Th1 differentiation and by 
reducing the MMP-9/TIMP-1 ratio. They further reported that when QRC was used in 
combination with IFN-ǃ, it has additive effects on the regulation of the levels of TNF-ǂ and 
MMP-9 [Sternberg et al., 2008]. The enzymes gelatinases A (MMP-2) and B (MMP-9) are 
involved in the pathogenesis of MS [Bever and Rosenberg, 1999; Mandler et al., 2001]. Liuzzi 
et al. reported that the non-flavonoids resveratrol (RSV) and tyrosol/hydroxytyrosol 
(Oliplus), but not the flavonoids QRC and catechins [green tea extract (GTE)], dose-
dependently inhibit the expression of MMP-2 and MMP-9 in LPS-activated primary rat 
astrocytes. In turn, the direct inhibition of MMP2 and MMP-9 was achieved completely by 
QRC and GTE, not by RSV, and only partially by oliplus in cell-free systems of MS sera. 
These results indicate that the flavonoids and non-flavonoids tested exert their inhibitory 
effect on MMPs, displaying different mechanisms of action, possibly related to their 
structure; this indicates that their combined use may represent a powerful tool for the 
downregulation of MMPs in the course of MS [Liuzzi et al.]. 
6.2 Fumarate linking to Nrf2 pathway to protect MS 
The antioxidant-responsive element (ARE) is an enhancer element that triggers the 
transcription of a battery of genes encoding phase II detoxification enzymes [Rushmore et 
al., 1991; Rushmore and Pickett, 1990] and factors vital for neuronal survival [Lee et al., 
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2005]. The ARE is activated through the binding of its transcription factor NF–E2-related 
factor 2 (Nrf2) [Moi et al., 1994; Venugopal and Jaiswal, 1996]. Nrf2–ARE activation is a 
critical neuroprotective pathway that confers resistance to a variety of oxidative, stress-
related, neurodegenerative injuries [Johnson et al., 2008]. Evidentially, autopsy studies of 
MS-affected tissue have revealed that neuronal Nrf2 is also activated during the natural 
course of MS, which is similar to the observations made in untreated EAE [Linker et al.]. 
Furthermore, van Horssen et al. showed that invading leukocytes contribute to cell damage 
and demyelination by producing excessive amounts of cytotoxic mediators, including ROS, 
and that to neutralize the destructive effects of ROS, the CNS is endowed with a repertoire 
of endogenous antioxidant enzymes, which are regulated by the transcription factor Nrf2; 
on the basis of these findings, they suggested that persistent Nrf2-mediated transcription 
occurs in active MS lesions, but this endogenous response is insufficient to prevent ROS-
induced cellular damage, which is abundant in inflammatory MS lesions [van Horssen et 
al.]. Accordingly, overexpression of Nrf2/ARE-regulated antioxidants in EAE and MS tissue 
is indicative of ongoing OS [Schreibelt et al., 2007]. Furthermore, Linker et al. reported the 
Nrf2 pathway was activated by dimethyl fumarate or monomethyl fumarate [Linker et al.]. 
They showed that dimethylfumarate exerts protective effects on oligodendrocytes, myelin, 
axons, and neurons in vivo and reduces the oxidative stress in MOG-EAE models; their 
study also provided evidence that the proper functioning of Nrf2 is required for the 
therapeutic effect of dimethylfumarate, suggesting that the CNS-protective effects of 
dimethylfumarate involve the activation of Nrf2-mediated OS response mechanisms, which 
is an important protective mechanism of the CNS in a variety of pathological conditions. A 
phase II trial is currently underway to examine the applicability of fumarate as a disease-
modifying agent in MS patients [Barten et al., 2010].  
6.3 Other extracts from plants to benefit MS 
De Paula et al. found that genistein, which occurs abundantly in soy products, has 
apoptotic, antioxidant, and anti-inflammatory properties. They observed that genistein 
treatment significantly ameliorated the severity of EAE, modulating pro- and anti-
inflammatory cytokines and decreasing the rolling and adhering of leukocytes, which imply 
that genistein may have potential as a therapeutic agent for MS [De Paula et al., 2008]. 
Another antioxidant compound, silymarin—a purified extract from milk thistle (Silybum 
marianum)—is composed of a mixture of 4 isomeric flavonolignans: silibinin (main active 
component), isosilibinin, silydianin, and silychristin. This extract has been empirically used 
as a remedy for almost 2000 years and continues to be used in the treatment of many types 
of acute and chronic liver diseases. Although it is routinely used in clinical practice as a 
hepatoprotectant, the mechanisms underlying its beneficial effects remain largely unknown 
[Crocenzi and Roma, 2006]. Min et al. reported that silibinin significantly reduced the 
histological signs of demyelination and inflammation in EAE and that silibinin 
downregulated the secretion of pro-inflammatory Th1 cytokines and upregulated the anti-
inflammatory Th2 cytokines in vitro in an Ag-nonspecific manner. Further, silibinin dose-
dependently inhibited the production of Th1 cytokines ex vivo, indicating that it is both 
immunosuppressive and immunomodulatory and may therefore be effective in the 
treatment of MS [Min et al., 2007]. 
Together, many antioxidant components extracted from natural foods or plants, such as 
flavonoids, luteolin, EGCG (extracted from green tea), genistein (occurring abundantly in 
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soy), and silibinin (the major pharmacologically active compound of silymarin, a fruit 
extract of S. marianum) have been proved to have not only health benefits but also the 
potential for use in the treatment of MS [Hutter and Laing, 1996; Mori et al., 2004; Sueoka et 
al., 2001; Theoharides, 2009]. 
7. Antioxidant and immunomodulatory effects of EPO in MS/EAE 
EPO exhibits both hematopoietic and tissue-protective effects via interaction with different 
receptors [Leist et al., 2004].  
Several experimental studies have shown that both EPO and EPO receptor (EpoR) are 
functionally expressed in the nervous system and that this cytokine has remarkable 
neuroprotective activity both in vitro, against different neurotoxicants, and in vivo, in 
animal models of experimental nervous system disorders [Bartesaghi et al., 2005]. Moreover, 
EPO has been proved to have the ability to cross the BBB and modulate astrocytes to protect 
the brain from ischemic damage and the spinal cord from injury in animal models 
[Bernaudin et al., 1999; Brines et al., 2000; Diaz et al., 2005]. The neuroprotective effects of 
EPO against neuronal death induced by ischemia and hypoxia have also been extensively 
studied in both in vitro and in vivo studies [Bernaudin et al., 1999; Gunnarson et al., 2009]. 
7.1 Cytoprotective interaction of EPO and HO-1  
A recent report indicated that the upregulation of HO-1 expression contributes to EPO-
mediated cytoprotection against myocardial ischemia–reperfusion injury [Burger et al., 
2009]. The neuroprotective action of EPO in ischemic and CNS degenerative models was 
mediated by Janus-tyrosine kinase 2 (Jak2) signaling and the subsequent activation of PI3-
K/Akt phosphorylation and NFκB cascades, which lead to the suppression of the CNS 
damage due to excitotoxins and the consequent generation of free radicals, including NO 
[Digicaylioglu and Lipton, 2001; Maiese et al., 2004]. Moreover, Sättler et al. showed that 
in rats with MOG-induced optic neuritis, the systemic administration of EPO resulted in a 
significant increase in the survival and function of retinal ganglion cells (RGC), the 
neurons that form the axons of the optic nerve; they also found that the neuroprotective 
effects of EPO were mediated by 3 independent intracellular signaling pathways 
involving the proteins phospho-Akt, phospho-MAPK 1 and 2, and Bcl-2m, which showed 
increased levels in vivo after EPO treatment [Sattler et al., 2004]. They also found that EPO 
in combination with a selective inhibitor of phosphatidylinositol 3-kinase (PI3-K) 
prevented the upregulation of phospho-Akt and the consecutive RGC rescue, thereby 
indicating that the PI3-K/Akt pathway in MOG-EAE has an essential influence on RGC 
survival under systemic EPO treatment [Sattler et al., 2004]. Interestingly, PI3K/Akt-
pathway-related responses to OS and apoptosis have also been shown to be mediated by the 
transcriptional regulation of HO-1 [Martin et al., 2004]. Previously, Lifshitz et al. 
demonstrated that the dendritic cells (DCs) are direct targets of EPO, to initiate the 
immune response through the overexpression of human EPO in transgenic mice in in vivo 
experiments and validate a higher expression of EPO-R mRNA from bone marrow-
derived DCs (BM-DCs) [Lifshitz et al., 2009]. Recent reports indicate that EPO exerts its 
cytoprotective effects in cardiac ischemia–reperfusion injury by inducing HO-1 expression 
[Burger et al., 2009] 
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7.2 Interaction of EPO, HO-1, and NO in EAE/MS  
Tzima et al. reported that myeloid HO-1 deficiency exacerbated EAE in mice and enhanced 
the infiltration of activated macrophages and Th17 cells (IL-17-producing CD4+ IL-17-
producing CD4+ T cells) in the CNS, and thus, they established HO-1 as a critical early 
mediator of the innate immune response [Tzima et al., 2009; Zwerina et al., 2005]. Liu 
showed that the inhibition of HO-1 expression resulted in marked exacerbation of EAE, 
suggesting that endogenous HO-1 expression plays an important protective role in EAE and 
that the targeted induction of HO-1 overexpression may represent a novel therapeutic 
strategy for the treatment of MS [Liu et al., 2001]. A study be Wu et al. at a center associated 
with ours revealed that the therapeutic induction of HO-1 expression ameliorates 
experimental murine membranous nephropathy via anti-oxidative, anti-apoptotic, and 
immunomodulatory mechanisms [Wu et al., 2008]. HO-1 overexpression has been proved to 
protect cells and tissues in a transgenic model of EAE [Panahian et al., 1999]. Moreover, 
Kumral et al. demonstrated that EPO exerts neuroprotective activity through the selective 
inhibition of NO overproduction in neonatal hypoxic–ischemic brain injury [Kumral et al., 
2004]. Furthermore, Yuan et delineated a novel potential of EPO on peripheral inflammatory 
modulation in a murine MOG-EAE model [Yuan et al., 2008].  
7.3 Immunomodulatory effects of EPO in EAE 
After EPO was found to have neuroprotective effects in murine models of EAE [Zhang et al., 
2005], it was introduced in humans and found to be effective in chronic progressive MS 
[Ehrenreich et al., 2007]. In our previous study, we found that EPO can enhance the 
expression of endogenous HO-1 either peripherally or locally in EAE; similarly, we 
observed that EPO-treated MOG-EAE mice exhibited upregulation of the splenic regulatory 
CD4+ T cells (Treg) and Th2 cells and downregulation of central Th1 and Th17 cells. We also 
obtained molecular evidence proving that EPO enhances the expression of endogenous HO-
1 and that it has potential immunomodulatory activity and causes the suppression of 
inflammatory response to EAE [Chen et al., 2010].  
We thus demonstrated the protective effects of EPO on EAE (Fig. 1a, b), and we observed 
significantly higher expression levels of endogenous HO-1 mRNA in the brain and a 
tendency for higher expression levels of endogenous HO-1 mRNA in the spinal cord and 
brain of the EPO-treated MOG-EAE mice than in those of the controls (Fig. 1c). Similarly, the 
expression levels of HO-1 mRNA in lymphocytes isolated from the CNS of MOG-EAE mice 
and controls differed significantly (Fig. 1c). Correspondingly, the protein levels of HO-1 in 
the spinal cord of EPO-treated MOG-EAE mice were higher than those of the controls (Fig. 
1d). We further confirmed the augmenting effects of EPO on HO-1 in situ. Encephalitogenic 
Th17 cells play an essential role in the pathogenesis of EAE [Bettelli et al., 2006]. Th1 cells 
facilitate the invasion of Th17 cells to the CNS during EAE [O'Connor et al., 2008]. Further, 
IL-4 produced by CNS-derived Th2 cells is crucial to regulate the inflammation in EAE 
[Ponomarev et al., 2007]. To study the Th lineages further, we isolated mononuclear cells 
from the CNS of MOG-EAE mice treated with EPO and controls. Interestingly, we observed 
significantly lower ratios of both Th1 and Th17 cells to CD4+ cells in the EPO-treated MOG-
EAE mice than in the controls; only a mildly increasing trend of encephalitogenic Th2 
cells/CD4+ cells was noted in the EPO-treated group (Fig. 2 a-b). These findings suggest that 
EPO has the ability to counteract encephalitogenic Th1 and Th17 cells in situ, at least in part, 
and protect neuronal cells in EAE.  
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Fig. 1. EPO lessens EAE and enhances HO-1 in situ. (a) Clinical score and (b) time of onset of 
EAE in C57BL/6 mice treated i.p. with PBS or EPO (100 U/100 l/mouse) on days 1, 3, 5, 
and 7 after s.c. immunization with MOG 35–55/CFA on day 0 and PTX i.p. on days 0 and 2. 
Each group contained 10 mice. Data represent means ± SEM. (c) Expression of HO-1 mRNA 
in the brain, spinal cord, or lymphocytes isolated from CNS of EPO-treated and PBS-treated 
(as control) MOG-EAE mice determined by real time PCR. Data in plots are expressed as 
mean ± SD from 3 independent experiments. Statistical significance was set at p < 0.05. (d) 
Western blot analysis of HO-1 expression in the brain and spinal cord of EPO-treated and 
control mice on day 14 after MOG injection. (partly adapted from Clin Exp Immunol. [Chen 
et al.])  
Furthermore, we observed a greater extent of staining for HO-1-positive splenocytes in 
EPO-treated MOG-EAE mice than in the controls (Fig. 3a); this was also reflected in a 
significantly greater mean fluorescence intensity (MFI) in flow cytometry of the splenic 
lymphocytes of EPO-treated MOG-EAE mice than those of the controls (Fig. 3b). Similarly, 
we found an increased ratio of encephalitogenic Th1 and Th17 cells in EPO-treated MOG-
EAE mice, however, only a mildly decreasing trend of splenic Th1 and Th17 cell subsets 
from EPO-treated MOG-EAE mice was noted. Instead, a significantly high ratio of splenic 
Th2 (Fig. 3a) was noted in the EPO-treated group than in the controls, and a notably 
significant elevation of splenic CD25+Foxp3+ CD4+ cells (Tregs) was observed in the EPO-
treated MOG-EAE mice (Fig. 3d).  
We observed that the mRNA expression of HO-1 showed a tendency to increase, while the 
protein expression of HO-1 was notably high in the spinal cord of EPO-treated MOG-EAE; 
in contrast, a significant elevation of HO-1 mRNA, but no significant expression of HO-1 
protein, was observed in the brain of EPO-treated MOG-EAE mice. Currently, Th17 cells are  
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Fig. 2. Distribution of Th lymphocyte subsets in situ. (a) Flow cytometric analysis of 
intracellular cytokines in CD4+ T cells isolated from CNS of mice treated with either EPO or 
PBS. CD4 T lymphocytes isolated from the CNS of EPO-treated mice or controls on day 21 at 
peak disease stage were intracellularly stained with IL-4, IFN- and IL-17 by flow 
cytometry. (b) Percentages of IFN--producing CD4+ T cells (Th1), IL-17-producing CD4+ T 
cells (Th17), and IL-4-producing CD4+ T cells (Th2) are presented. Data are representative of 
3 experiments. (partly adapted from Clin Exp Immunol. [Chen et al.]) 
believed to play a vital role in immunopathogenic mechanisms of EAE. However, Th1 cells 
are required to facilitate the CNS infiltration of Th17 cells in EAE [O'Connor et al., 2008]. 
Yuan et al. reported that short-tem EPO therapy for EAE can peripherally downregulate 
MHC class II of DCs and counteract Th17 cell responses [Yuan et al., 2008]. Our data 
confirmed further that EPO counteracts Th17 and Th1 cell inflammatory responses in EAE, 
both peripherally and centrally. EPO markedly reduced IL-6 levels in the spinal cord and 
decreased the inflammation and clinical score of EAE, thereby suggesting that the 
immunomodulatory activity of EPO may be partly mediated by the reduction of IL-6 levels 
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Fig. 3. EPO enhances splenic expression of HO-1, Th2 cells, and Treg. 
(a) Immunohistochemical staining for HO-1 expression in the spleen of EPO-treated mice 
(right) and controls (left) on day 14 after MOG injection. Images are at either 40 × (top) or 
400 × (bottom) magnification, and the length of the bar represents 50 m. (b) Splenic 
lymphocytes from EPO-treated mice and controls on day 14 of EAE were stained with FITC-
conjugated HO-1 for flow cytometry. Mean fluorescence intensity (MFI) of HO-1 staining 
was analyzed (b, left). Representative of 3 experiments. * indicates p < 0.05. (c) Splenic 
lymphocytes from EPO-treated mice and from controls were stained for Th1, Th2, and Th17 
cells for flow cytometry analysis of the proportion of total CD4 T cells. Data represent 4 
experiments. (d) These splenic lymphocytes were also stained for CD25+Foxp3+ CD4+ cells 
(Treg) by flow cytometry. Compared to controls, EPO-treated MOG-EAE mice had higher 
ratio of splenic Treg on day 14. Data of Treg represent 6 experiments. (partly adapted from 
Clin Exp Immunol. [Chen et al.])  
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[Agnello et al., 2002]. Tron et al. noted that the expression of HO-1 were elevated in a 
localized inflammation after intramuscular injection of inflammatory material and IL-6-
specific transcripts were introduced into the injured muscle and were in accordance with the 
serum levels of IL-6; these findings imply that the induction of HO-1 in local inflammation 
may affect other anti-inflammatory agents, such as local IL-6 [Tron et al., 2005]. Our data 
show that there is suppression of IL-6 mRNA in the CNS of EPO-treated MOG-EAE mice, 
which may be attributed to the overexpression of residential HO-1 to counteract IL-6 (Fig. 
2). However, further investigation is required to clarify this.  
We confirmed that exogenous EPO promotes the expression of endogenous HO-1, either in 
the CNS or the spleen, to repress Th1 and Th17 responses in situ and that it enhances the 
systemic invasion of Th2 and Tregs to reduce the severity of EAE. The potential role of EPO 
in upregulating the expression of endogenous HO-1 and, thereby, the anti-oxidative and 
anti-inflammatory activities of HO-1 indicate that EPO may have potential for clinical 
therapeutic application in autoimmune CNS disorders, such as MS. Taken together, these 
findings suggested that EPO not only causes the upregulation of HO-1 expression in the 
CNS but also acts as a potent inducer of HO-1 expression in the peripheral immunologic 
systems. Collectively, the neuroprotective action of EPO in EAE appears to involve different 
mechanisms of systemic and local inhibition of inflammation [Chen et al., 2010].  
8. Conclusion  
Patients with MS often experience difficulty in ambulation, spasticity, sensation, and 
cognition. The year 2010 marked the beginning of the era of oral medications for MS with 
the introduction of fingolimod [Brinkmann et al., 2010] as the first oral disease-modifying 
agent for MS. Subsequently other oral agents, including cladribine, teriflunomide, 
laquinimod, and dimethyl fumarate, as well as the monoclonal antibodies alemtuzumab, 
daclizumab, and rituximab have been used in MS [Gold, Krieger]. Currently, promising 
results have been obtained in Phase II trials of teriflunomide, daclizumab, laquinimod, and 
an antioxidant agent-fumarate [Barten et al., 2010]. 
However, to date, no specific drugs have been developed to completely cure MS.  
Considering the data gathered from studies, such as those on animal models of EAE, it can 
be inferred that antioxidant molecules may be beneficial to some extent for adjuvant therapy 
in MS [Mirshafiey and Mohsenzadegan, 2009; van Horssen et al., 2008; van Horssen et al., 
2010]. Although some antioxidants have shown some degree of efficacy in EAE, little 
information is available on the effect of their use in MS [Mirshafiey and Mohsenzadegan, 
2009; Schreibelt et al., 2007]. Nevertheless, antioxidant therapy can be considered a 
candidate for use as adjuvant therapy in MS. 
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